Right holders may voluntarily provide licenses to generic manufacturers. Voluntary licenses are producing promising results in the area of HIV, but do not yet address increasing needs across a broader range of health technologies. Full incorporation and use of TRIPS flexibilities will thus continue to be important to encourage pharmaceutical companies to license their products in order to increase access while not discouraging innovation.